Cargando…
In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195286/ https://www.ncbi.nlm.nih.gov/pubmed/34122134 http://dx.doi.org/10.3389/fphys.2021.661413 |
_version_ | 1783706475221221376 |
---|---|
author | Doisne, Nicolas Grauso, Marta Mougenot, Nathalie Clergue, Michel Souil, Charlotte Coulombe, Alain Guicheney, Pascale Neyroud, Nathalie |
author_facet | Doisne, Nicolas Grauso, Marta Mougenot, Nathalie Clergue, Michel Souil, Charlotte Coulombe, Alain Guicheney, Pascale Neyroud, Nathalie |
author_sort | Doisne, Nicolas |
collection | PubMed |
description | Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R104W variant, inducing retention of wild-type (WT) channels and leading to a drastic reduction of the resulting Na(+) current (I(Na)). To explore this dominant-negative effect in vivo, we created a murine model using adeno-associated viruses (AAVs). METHODS: Due to the large size of SCN5A, a dual AAV vector strategy was used combining viral DNA recombination and trans-splicing. Mice were injected with two AAV serotypes capsid 9: one packaging the cardiac specific troponin-T promoter, the 5′ half of hSCN5A cDNA, a splicing donor site and a recombinogenic sequence; and another packaging the complementary recombinogenic sequence, a splicing acceptor site, the 3′ half of hSCN5A cDNA fused to the gfp gene sequence, and the SV40 polyA signal. Eight weeks after AAV systemic injection in wild-type (WT) mice, echocardiography and ECG were recorded and mice were sacrificed. The full-length hSCN5A-gfp expression was assessed by western blot and immunohistochemistry in transduced heart tissues and the Na(+) current was recorded by the patch-clamp technique in isolated adult GFP-expressing heart cells. RESULTS: Almost 75% of the cardiomyocytes were transduced in hearts of mice injected with hNa(v)1.5 and ∼30% in hNa(v)1.5-R104W overexpressing tissues. In ventricular mice cardiomyocytes expressing R104W mutant channels, the endogenous I(Na) was significantly decreased. Moreover, overexpression of R104W channels in normal hearts led to a decrease of total Na(v)1.5 expression. The R104W mutant also induced a slight dilatation of mice left ventricles and a prolongation of RR interval and P-wave duration in transduced mice. Altogether, our results demonstrated an in vivo dominant-negative effect of defective R104W channels on endogenous ones. CONCLUSION: Using a trans-splicing and viral DNA recombination strategy to overexpress the Na(+) channel in mouse hearts allowed us to demonstrate in vivo the dominant-negative effect of a BrS variant identified in the N-terminus of Na(v)1.5. |
format | Online Article Text |
id | pubmed-8195286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81952862021-06-12 In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant Doisne, Nicolas Grauso, Marta Mougenot, Nathalie Clergue, Michel Souil, Charlotte Coulombe, Alain Guicheney, Pascale Neyroud, Nathalie Front Physiol Physiology Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R104W variant, inducing retention of wild-type (WT) channels and leading to a drastic reduction of the resulting Na(+) current (I(Na)). To explore this dominant-negative effect in vivo, we created a murine model using adeno-associated viruses (AAVs). METHODS: Due to the large size of SCN5A, a dual AAV vector strategy was used combining viral DNA recombination and trans-splicing. Mice were injected with two AAV serotypes capsid 9: one packaging the cardiac specific troponin-T promoter, the 5′ half of hSCN5A cDNA, a splicing donor site and a recombinogenic sequence; and another packaging the complementary recombinogenic sequence, a splicing acceptor site, the 3′ half of hSCN5A cDNA fused to the gfp gene sequence, and the SV40 polyA signal. Eight weeks after AAV systemic injection in wild-type (WT) mice, echocardiography and ECG were recorded and mice were sacrificed. The full-length hSCN5A-gfp expression was assessed by western blot and immunohistochemistry in transduced heart tissues and the Na(+) current was recorded by the patch-clamp technique in isolated adult GFP-expressing heart cells. RESULTS: Almost 75% of the cardiomyocytes were transduced in hearts of mice injected with hNa(v)1.5 and ∼30% in hNa(v)1.5-R104W overexpressing tissues. In ventricular mice cardiomyocytes expressing R104W mutant channels, the endogenous I(Na) was significantly decreased. Moreover, overexpression of R104W channels in normal hearts led to a decrease of total Na(v)1.5 expression. The R104W mutant also induced a slight dilatation of mice left ventricles and a prolongation of RR interval and P-wave duration in transduced mice. Altogether, our results demonstrated an in vivo dominant-negative effect of defective R104W channels on endogenous ones. CONCLUSION: Using a trans-splicing and viral DNA recombination strategy to overexpress the Na(+) channel in mouse hearts allowed us to demonstrate in vivo the dominant-negative effect of a BrS variant identified in the N-terminus of Na(v)1.5. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8195286/ /pubmed/34122134 http://dx.doi.org/10.3389/fphys.2021.661413 Text en Copyright © 2021 Doisne, Grauso, Mougenot, Clergue, Souil, Coulombe, Guicheney and Neyroud. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Doisne, Nicolas Grauso, Marta Mougenot, Nathalie Clergue, Michel Souil, Charlotte Coulombe, Alain Guicheney, Pascale Neyroud, Nathalie In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title | In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title_full | In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title_fullStr | In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title_full_unstemmed | In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title_short | In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant |
title_sort | in vivo dominant-negative effect of an scn5a brugada syndrome variant |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195286/ https://www.ncbi.nlm.nih.gov/pubmed/34122134 http://dx.doi.org/10.3389/fphys.2021.661413 |
work_keys_str_mv | AT doisnenicolas invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT grausomarta invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT mougenotnathalie invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT clerguemichel invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT souilcharlotte invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT coulombealain invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT guicheneypascale invivodominantnegativeeffectofanscn5abrugadasyndromevariant AT neyroudnathalie invivodominantnegativeeffectofanscn5abrugadasyndromevariant |